Pan-Cdk inhibitor ZK304709 suppresses Cdc20 expression and potentiates the anticancer activity of apcin in HeLa cervical cancer cells
Acta Pharmaceutica · 2025
DOI: 10.2478/acph-2026-0002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica, 2025. Verfasst von Xiangyang Le und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China. Hauptthemen laut MEDLINE: Cdc20 Proteins, Uterine Cervical Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cell division cycle 20 homologue (Cdc20), a key regulator of the anaphase-promoting complex/cyclosome (APC/C), is frequently overexpressed in human cancers and represents a promising therapeutic target. However, monotherapy targeting Cdc20 has shown limited efficacy, partly due to compensatory activation of cyclin-dependent kinase 1 (Cdk1). In this study, we investigated the combinatorial potential of the pan-Cdk inhibitor ZK304709 with the Cdc20 inhibitor apcin in HeLa cervical cancer cells. Transcriptomic analysis revealed that both CDC20 and CDK1 are upregulated in cervical cancer tissues. Mechanistically, apcin treatment induced cyclin B1 accumulation and enhanced Cdk1 phosphorylation at Thr161, suggesting feedback activation. In contrast, ZK304709 reduced p -Cdk1(T161) levels and suppressed Cdc20 expression at both protein and mRNA levels. Functionally, the combination of apcin and ZK304709 synergistically inhibited cell proliferation and induced G2/M phase arrest in HeLa cells. These findings demonstrate that dual inhibition of Cdk1 and Cdc20 disrupts compensatory signalling pathways and enhances antitumour efficacy in HeLa cells, providing a rational strategy for combination therapy in cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China.
- 2Department of Pharmacy, Yiyang Central Hospital, Yiyang 413000 Hunan, China.
- 3Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases Changsha 410013, Hunan, China.
- 4Hunan Key Laboratory of Organ Fibrosis, Changsha 410013, Hunan China.
ORCID-Profile: Xiangyang Le, Qingsong Chen, Shuyang Cao, Qianbin Li, Zhuo Chen
Zitieren
APA
Le, X., Chen, Q., Cao, S., Hu, G., Li, Q., & Chen, Z. (2025). Pan-Cdk inhibitor ZK304709 suppresses Cdc20 expression and potentiates the anticancer activity of apcin in HeLa cervical cancer cells. Acta Pharmaceutica. https://doi.org/10.2478/acph-2026-0002
Vancouver
Le X, Chen Q, Cao S, Hu G, Li Q, Chen Z. Pan-Cdk inhibitor ZK304709 suppresses Cdc20 expression and potentiates the anticancer activity of apcin in HeLa cervical cancer cells. Acta Pharmaceutica. 2025. doi:10.2478/acph-2026-0002
BibTeX
@article{Le2025,
author = {Le, Xiangyang and Chen, Qingsong and Cao, Shuyang and Hu, Gaoyun and Li, Qianbin and Chen, Zhuo},
title = {Pan-Cdk inhibitor ZK304709 suppresses Cdc20 expression and potentiates the anticancer activity of apcin in HeLa cervical cancer cells},
journal = {Acta Pharmaceutica},
year = {2025},
doi = {10.2478/acph-2026-0002}
}
EUVIMED